FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:669-670 September 8, 1994 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Concern about cost now dominates many decisions about the use of drugs and other therapeutic interventions. Increasingly, such decisions are being influenced by published economic analyses that relate the effectiveness of treatments and their associated costs (cost-effectiveness analyses). Many of these analyses are supported by grants from the National Institutes of Health (NIH) or other neutral sources. Some, however, are funded by companies that hope these analyses will put their products in a favorable light¹. Companies might then even use particularly favorable analyses to justify the prices of new drugs.

A cost-effectiveness analysis is usually performed by developing a . . . [Full Text of this Article]

References

Related Letters:

Cost-Effectiveness Analyses
Steinberg E. P., Powe N. R., Schulman K., Simonich W. L., Tilson H., Kotsanos J. G., Flanagin A., Rennie D., Kassirer J. P., Angell M.
Extract | Full Text  
N Engl J Med 1995; 332:123-125, Jan 12, 1995. Correspondence

This article has been cited by other articles:

• American College of Physicians, (2008). Information on Cost-Effectiveness: An Essential Product of a National Comparative Effectiveness Program. ANN INTERN MED 148: 956-961 [Abstract] [Full Text]  
• McCabe, C. (2007). Guidance on Good Practice in Cost-Effectiveness Modeling: Is More Needed?. Med Decis Making 27: 350-351  
• Detsky, A. S., Laupacis, A. (2007). Relevance of Cost-effectiveness Analysis to Clinicians and Policy Makers. JAMA 298: 221-224 [Full Text]  
• Wynia, M. (2006). Cost-effectiveness Analysis in the United States. JAMA 295: 2722-2722 [Full Text]  
• Bell, C. M, Urbach, D. R, Ray, J. G, Bayoumi, A., Rosen, A. B, Greenberg, D., Neumann, P. J (2006). Bias in published cost effectiveness studies: systematic review. BMJ 332: 699-703 [Abstract] [Full Text]  
• Rizzo, V. M., Fortune, A. E. (2006). Cost Outcomes and Social Work Practice. Research on Social Work Practice 16: 5-8  
• Neumann, P. J., Rosen, A. B., Weinstein, M. C. (2005). Medicare and Cost-Effectiveness Analysis. NEJM 353: 1516-1522 [Full Text]  
• Williams, L. S., Holloway, R. G. (2005). Editorial Comment: How Much Is a Good Night's Sleep Worth?. Stroke 36: 1293-1294 [Full Text]  
• Welsing, P. M. J., Severens, J. L., Laan, R. F. J. M. (2003). Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result. Rheumatology (Oxford) 42: 1574-1575 [Full Text]  
• Schulman, K. A., Seils, D. M., Timbie, J. W., Sugarman, J., Dame, L. A., Weinfurt, K. P., Mark, D. B., Califf, R. M. (2002). A National Survey of Provisions in Clinical-Trial Agreements between Medical Schools and Industry Sponsors. NEJM 347: 1335-1341 [Abstract] [Full Text]  
• Cohen, D. J., Cosgrove, R. S., Berezin, R. H., Teirstein, P. S., Leon, M. B., Kuntz, R. E., on behalf of the Gamma-1 Investigators, (2002). Cost-Effectiveness of Gamma Radiation for Treatment of In-Stent Restenosis: Results From the Gamma-1 Trial. Circulation 106: 691-697 [Abstract] [Full Text]  
• Jacklin, P. B., Barrington, S. F., Roxburgh, J. C., Jackson, G., Sariklis, D., West, P. A., Maisey, M. N. (2002). Cost-effectiveness of preoperative positron emission tomography in ischemic heart disease. Ann. Thorac. Surg. 73: 1403-1409 [Abstract] [Full Text]  
• Ramsey, S. D., Moinpour, C. M., Lovato, L. C., Crowley, J. J., Grevstad, P., Presant, C. A., Rivkin, S. E., Kelly, K., Gandara, D. R. (2002). Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer. JNCI J Natl Cancer Inst 94: 291-297 [Abstract] [Full Text]  
• Singer, M. E., Applegate, K. E. (2001). Cost-Effectiveness Analysis in Radiology. Radiology 219: 611-620 [Abstract] [Full Text]  
• Serruys, P. W., de Bruyne, B., Carlier, S., Sousa, J. E., Piek, J., Muramatsu, T., Vrints, C., Probst, P., Seabra-Gomes, R., Simpson, I., Voudris, V., Gurne, O., Pijls, N., Belardi, J., van Es, G.-A., Boersma, E., Morel, M.-A., van Hout, B. (2000). Randomized Comparison of Primary Stenting and Provisional Balloon Angioplasty Guided by Flow Velocity Measurement. Circulation 102: 2930-2937 [Abstract] [Full Text]  
• Hillner, B. E., Roberts, J. D. (2000). Role of Perspective and Other Uncertainties in Cost-Effectiveness Assessments in Advanced Prostate Cancer. JNCI J Natl Cancer Inst 92: 1704-1706 [Full Text]  
• Stafford, M., Messori, A., Trippoli, S., Daealessandro, P., Di Giorgio, D., Tosolini, F., Hill, S., Henry, D., Mitchell, A., Rennie, D., Luft, H. S. (2000). Problems in Pharmacoeconomic Analyses. JAMA 284: 1922-1924 [Full Text]  
• Neumann, P. J., Stone, P. W., Chapman, R. H., Sandberg, E. A., Bell, C. M. (2000). The Quality of Reporting in Published Cost-Utility Analyses, 1976-1997. ANN INTERN MED 132: 964-972 [Abstract] [Full Text]  
• Hill, S. R., Mitchell, A. S., Henry, D. A. (2000). Problems With the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 283: 2116-2121 [Abstract] [Full Text]  
• Rennie, D., Luft, H. S. (2000). Pharmacoeconomic Analyses: Making Them Transparent, Making Them Credible. JAMA 283: 2158-2160 [Full Text]  
• Krimsky, S. (1999). Conflict of Interest and Cost-effectiveness Analysis. JAMA 282: 1474-1475 [Full Text]  
• Holloway, R. G., Benesch, C. G., Rahilly, C. R., Courtright, C. E. (1999). A Systematic Review of Cost-Effectiveness Research of Stroke Evaluation and Treatment. Stroke 30: 1340-1349 [Abstract] [Full Text]  
• Giacomini, M. K. (1999). The Which-Hunt:Assembling Health Technologies for Assessment and Rationing. Journal of Health Politics, Policy and Law 24: 715-758 [Abstract]  
• Jefferson, T., Smith, R., Yee, Y., Drummond, M., Pratt, M., Gale, R. (1998). Evaluating the BMJ Guidelines for Economic Submissions: Prospective Audit of Economic Submissions to BMJ and The Lancet. JAMA 280: 275-277 [Abstract] [Full Text]  
• Drummond, M. F. (1998). Experimental versus Observational Data in the Economic Evaluation of Pharmaceuticals. Med Decis Making 18: S12-S18  
• Pausjenssen, A. M., Detsky, A. S. (1998). Guidelines for Measuring the Costs and Consequences of Adopting New Pharmaceutical Products: Are They on Track?. Med Decis Making 18: S19-S22  
• Neumann, P. J. (1998). Paying the Piper for Pharmacoeconomic Studies. Med Decis Making 18: S23-S26  
• Stammers, A. H (1998). Monitoring controversies during cardiopulmonary bypass: how far have we come?. Perfusion 13: 35-43  
• Drummond, M F, Jefferson, T O (1996). Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 313: 275-283 [Full Text]  
• Soumerai, S. B., Lipton, H. L. (1995). Computer-Based Drug-Utilization Review -- Risk, Benefit, or Boondoggle?. NEJM 332: 1641-1645 [Full Text]  
• Sarcristan, J A, Hernandez, J. M (1995). Criteria for authorship. BMJ 310: 869-869 [Full Text]  
• Steinberg, E. P., Powe, N. R., Schulman, K., Simonich, W. L., Tilson, H., Kotsanos, J. G., Flanagin, A., Rennie, D., Kassirer, J. P., Angell, M. (1995). Cost-Effectiveness Analyses. NEJM 332: 123-125 [Full Text]  
• Kessler, D. A., Rose, J. L., Temple, R. J., Schapiro, R., Griffin, J. P. (1994). Therapeutic-Class Wars -- Drug Promotion in a Competitive Marketplace. NEJM 331: 1350-1353 [Full Text]